

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of Reporting Person [*] Grachev Igor D	2. Date of Event Requiring Statement (Month/Day/Year) 01/06/2020	3. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]					
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE	01/00/2020	Issuer (Check all applicable) Director 10% Owner			5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street) FLORHAM, NJ 07932					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned						
1. Title of Security (Instr. 4)	curities ned	1	4. Natur (Instr. 5	e of Indirect Beneficial Ownership)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exer	rcisable	3. Tit	le and Amount of	4. Conversion	5. Ownership	6. Nature of Indirect Beneficial
(Instr. 4)	and Expiration Date		Securities Underlying Derivative		or Exercise	Form of	Ownership
	(Month/Day/Year)		Security		Price of	Derivative	(Instr. 5)
			(Instr. 4)			Security: Direct	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	2	(D) or Indirect (I)	
				Shares		(Instr. 5)	

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Grachev Igor D C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM, NJ 07932			Chief Medical Officer		

Signatures

01/08/2020
Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Exhibit 24

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Gregory J. Lynch, Joshua B. Erekson, Stacy Fredericks, and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Gregory J. Lynch, Joshua B. Erekson, Stacy Fredericks, and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The undersigned acknowledges that Gregory J. Lynch, Joshua B. Erekson, Stacy Fredericks, and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: January 2, 2020

Signed: /s/ Igor Grachev

Print Name: Igor Grachev